Citi lowered the firm’s price target on 2seventy Bio to $9 from $11 and keeps a Buy rating on the shares. The analyst continues to anticipate Abecma revenue growth in 2024 driven by label expansion, but acknowledges the near-term uncertainty for Abecma’s commercial performance. The firm now sees a more gradual launch.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TSVT: